InVivo Therapeutics Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of InVivo Therapeutics Holdings generated cash of -$10,482,000, which is less than the previous year. Cash used in financing activities reached the amount of $7,962,000 last year. Net change in cash is therefore -$2,680,000.
Cash Flow
| 2013 | -14.90M | -748.46K | 16.80M |
|---|---|---|---|
| 2014 | -15.28M | -2K | 14.76M |
| 2015 | -16.32M | -5K | 23.06M |
| 2016 | -16.74M | -6.50M | 29.79M |
| 2017 | -19.68M | 11.51M | -383K |
| 2018 | -12.31M | -65K | 15.88M |
| 2019 | -10.31M | -12K | 268K |
| 2020 | -9.53M | -41K | 22.46M |
| 2021 | -8.85M | -77K | 8.50M |
| 2022 | -10.48M | -160K | 7.96M |
NVIV Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 19.18M | 19.60M | 6.71M | 16.77M | 13.27M | 21.46M | 14.92M | 13.45M | 13.98M | 12.82M |
Operating activities | ||||||||||
Net income | -10.49M | -9.89M | -9.07M | -11.83M | -23.42M | -26.74M | -23.43M | -33.31M | -18.34M | -38.75M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 445K | 372K | 329K | 322K | 91K | 395K | 553K | 689K | 752K | 740.69K |
Stock-based compensation expense | 159K | 315K | 215K | 268K | 618K | 4.10M | 5.06M | 4.66M | 3.20M | 3.13M |
| Deferred income tax benefit | 159K | 315K | 215K | 268K | 618K | 4.10M | 5.06M | 4.66M | 3.20M | 3.13M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 12K | 124K | -461K | 127K | -173K | -23K | 489K | -48K | -330K | -253.29K |
Cash generated by operating activities | -10.48M | -8.85M | -9.53M | -10.31M | -12.31M | -19.68M | -16.74M | -16.32M | -15.28M | -14.90M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -8.25M | -18.91M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -160K | -77K | -41K | -12K | -65K | -65K | -107K | -5K | -47K | -748.46K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -160K | -77K | -41K | -12K | -65K | 11.51M | -6.50M | -5K | -2K | -748.46K |
Financing activities | ||||||||||
Common Stock Issued | 7.96M | 8.50M | 22.11M | 367K | 16.51M | 51K | 29.99M | 14.48M | 14.61M | 16.40M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | -752K | 0 | -395K | 0 | -77K | -89.89K |
Cash used in financing activities | 7.96M | 8.50M | 22.46M | 268K | 15.88M | -383K | 29.79M | 23.06M | 14.76M | 16.80M |
Net Change In Cash | -2.68M | -422K | 12.88M | -10.05M | 3.50M | -8.55M | 6.54M | 6.73M | -521K | 1.15M |
Cash at end of period | 16.50M | 19.18M | 19.60M | 6.71M | 16.77M | 12.91M | 21.46M | 20.19M | 13.45M | 13.98M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |